D4 receptor Inhibitors
1 drugsAbout D4 receptor
The D4 receptor is a dopamine receptor family member and a G protein-coupled receptor (GPCR) crucial in neurotransmission. It influences various physiological processes within the central nervous system (CNS).
The D4 receptor's involvement in dopamine signaling pathways makes it a therapeutic target for CNS disorders. Currently, there is no genetic evidence directly linking the D4 receptor to specific diseases.
ONAPGO is the only FDA-approved drug targeting the D4 receptor, a small molecule approved in 2025. MDD US is the sole company with an approved drug for this target, addressing CNS indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Postoperative Pain Management with only 2 trials.
Top D4 receptor Drugs
MDD US is the only company with an approved drug targeting the D4 receptor.
Low competition presents an opportunity, but also indicates potential challenges in the target's validation.
D4 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets D4 receptor, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
D4 receptor Clinical Trials 9 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 | 0% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
D4 receptor Drug Approval Timeline (2025 - 2025)
The first and only drug, ONAPGO, was approved in 2025, representing a short approval span of 1 year.
Recent approval suggests renewed interest, but limited history indicates uncertainty in long-term success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 138 clinical trials targeting D4 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities